Questionnaire

1. Contributors to the rise of CVD morbidity and mortality in South Africa are high rates of:

2. The leading modifiable risk factor contributing to the burden of CVD is:

3. The cardiovascular risk conferred by having comorbid hypertension and dyslipidaemia is four-fold higher than in those having only one of these risk factors.

4. Sub-analysis of the ASCOT trial found that the reduction in cardiovascular events was significantly greater for participants treated with:

5. The 2023 ESH-recommended first-line therapy for the treatment of essential hypertension is:

6. The risks for chronic heart disease and stroke are greater in patients with night-time hypertension.

7. Immediate BP-lowering treatment is recommended for patients with grade 2 hypertension, defined as an office BP level of:

8. 24-hour BP reductions are achieved when using a once-daily dose of:

9. Perindopril, when used alone or in combination with indapamide or amlodipine, demonstrates a significantly reduced risk for:

10. Twenty-year follow-up data from ASCOT Legacy demonstrates that amlodipine with or without perindopril significantly reduces the risk for:

11. A diuretic with a neutral metabolic effect is:

12. Compared with ARBs, ACEis consistently demonstrate greater mortality risk reduction among patients who have:

13. The addition of perindopril to existing β-blocker treatment significantly reduces the risk for stroke.

14. A β-blocker that has a neutral metabolic effect is:

15. Compared with usual care in patients with mild-to-moderate hypertension, the TRIUMPH trial demonstrated that triple SPC antihypertensive therapy: